Get the weekly note
ETFIQetfiq.com · independent ETF data

Data as of .

BBH vs PBE: which is really different?

BBH and PBE hold 44% of their weight in the same names, and BBH returned more over the year.

VanEck Biotech ETF and Invesco Biotechnology & Genome ETF.

60.4%BBH in the S&P 500
30.0%PBE in the S&P 500
+40.5%BBH total return, 1 year
+36.2%PBE total return, 1 year

ETFIQ Off-Index Score: BBH scores higher

How much of it is not the index it is sold as an alternative to?

BBH 61.7PBE 61.70.1, the lowest in this set91.8, the highest

A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed

BBH40% of its weight is outside the S&P 500 · 1 year to Sep 18, 2026
60%40%of its weight in S&P 500 companiesof its weight outside the S&P 500active share 99% · top ten 72% of the fund · 24 holdings filed Sep 17, 2026 · Nasdaq-100: 47% in60%40%in the S&P 500outsideactive share 99% · top ten 72% of the fund
PBE70% of its weight is outside the S&P 500 · 1 year to Sep 18, 2026
30%70%in the S&P 500of its weight outside the S&P 500active share 99% · top ten 47% of the fund · 33 holdings filed Sep 19, 2026 · Nasdaq-100: 20% in30%70%inoutside the S&P 500active share 99% · top ten 47% of the fund

44% of the two portfolios are the same securities at the same weight.

What they hold in common

By the books each fund has filed, BBH and PBE hold 44% of their money in the same securities at the same weight.

Positions BBH and PBE both hold, largest shared weight first
HoldingBBHPBE
Gilead Sciences Inc13.81%5.27%
Natera Inc4.97%5.70%
Regeneron Pharmaceuticals Inc7.00%4.89%
Vertex Pharmaceuticals Inc8.32%4.77%
Amgen Inc15.03%4.53%
Illumina Inc3.68%5.53%
Moderna Inc5.05%2.75%
Biogen Inc2.71%5.07%
Incyte Corp2.39%2.73%
United Therapeutics Corp2.12%2.70%
Neurocrine Biosciences Inc1.50%2.70%
Biomarin Pharmaceutical Inc1.25%2.74%
Only in each
Only in BBHOnly in PBE
Argenx Se 4.93%Royalty Pharma PLC 4.88%
Iqvia Holdings Inc 4.61%Novavax Inc 3.03%
Revolution Medicines Inc 4.09%Sarepta Therapeutics Inc 3.01%
Guardant Health Inc 3.15%Exelixis Inc 2.91%
Beone Medicines Ltd 2.75%Halozyme Therapeutics Inc 2.91%
Alnylam Pharmaceuticals Inc 2.73%TG Therapeutics Inc 2.91%
Insmed Inc 2.31%Repligen Corp 2.76%
Biontech Se 1.62%Protagonist Therapeutics Inc 2.69%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 18, 2026 and Sep 19, 2026.

Performance, window by window

BBH and PBE over each window. Every figure is an ETFIQ calculation with distributions reinvested. Source: ETFIQ.
WindowTotal returnvs the S&P 500vs the Nasdaq-100
BBHPBEBBHPBEBBHPBE
3 months+24.8%+13.2%+22.5 pts+11.0 pts+27.3 pts+15.7 pts
6 months+29.0%+25.9%+11.0 pts+7.8 pts+4.8 pts+1.6 pts
1 year+40.5%+36.2%+23.9 pts+19.6 pts+18.7 pts+14.4 pts
3 years+48.9%+65.0%−29.5 pts−13.4 pts−49.3 pts−33.1 pts
Since launch+732.7%+492.4%−70.8 pts−311.1 pts−957.5 pts−1197.8 pts
Open the live comparison on ETFIQ
BBH and PBE on the same fields, as of Sep 18, 2026. Source: ETFIQ.
BBH
VanEck Biotech ETF
Holds 24 stocks in biotech, 60% of its weight in S&P 500 companies
PBE
Invesco Biotechnology & Genome ETF
Holds 33 stocks in biotech, 30% of its weight in S&P 500 companies
IssuerVanEckInvesco
ThemeBiotechBiotech
In the S&P 50060.4%30.0%
Active share vs the S&P 50099.0%99.0%
In the Nasdaq-10047.2%19.5%
Holdings2433
Top ten, share of the fund72.4%46.7%
Expense ratio0.35%0.59%
Fee for the differing part0.35%0.60%
Total return, 1 year+40.5%+36.2%
vs the S&P 500+23.9 pts+19.6 pts
vs the Nasdaq-100+18.7 pts+14.4 pts
Below its high−4.0%−3.9%
Net assets$470m$414m

BBH in plain words

By weight, 60% of BBH's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 72% of the fund across 24 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +40.5% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 23.9 pts.

PBE in plain words

By weight, 30% of PBE's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 47% of the fund across 33 positions, as published by its issuer for Sep 19, 2026. Over the year to Sep 18, 2026 the fund returned +36.2% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 19.6 pts.

Questions people ask

Do BBH and PBE hold the same stocks?
By their latest filings, 44% of their books are the same securities at the same weight, which is a meaningful overlap. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, BBH or PBE?
BBH has 60% of its weight in S&P 500 names and PBE has 30%, so BBH differs more from the index.
Which is cheaper, BBH or PBE?
BBH charges 0.35% a year and PBE charges 0.59%, so BBH is cheaper. Fees come from each fund's prospectus.

Other comparisons

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

BBH against PBE, ETFIQ, data as of Sep 18, 2026. Every figure is calculated from a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, BBH against PBE, data as of Sep 18, 2026. https://etfiq.com/compare/themes/bbh-vs-pbe Free to use with attribution; the underlying files are at Open data.

How every figure is computed · Standards and sources